HAUS6

Summary

HAUS6 (HAUS augmin like complex subunit 6, HGNC:25948) is a protein-coding gene on chromosome 9p22.1, encoding HAUS augmin-like complex subunit 6 (Q7Z4H7). Contributes to mitotic spindle assembly, maintenance of centrosome integrity and completion of cytokinesis as part of the HAUS augmin-like complex. It is a common-essential gene (DepMap: required in 99.1% of cancer cell lines).

The protein encoded by this gene is a subunit of the augmin complex. The augmin complex plays a role in microtubule attachment to the kinetochore and central spindle formation. This protein may have a role in efficient chromosome congression and segregation by promoting microtubule-dependent microtubule amplification. Pseudogenes of this gene are located on chromosomes 7 and 20. Alternative splicing results in multiple transcript variants that encode different protein isoforms.

Source: NCBI Gene 54801 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 179 total
• Cancer dependency (DepMap): dependent in 99.1% of screened cell lines (common-essential)
• MANE Select transcript: NM_017645

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25948
Approved symbol	HAUS6
Name	HAUS augmin like complex subunit 6
Location	9p22.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ20060, KIAA1574, dgt6
Ensembl gene	ENSG00000147874
Ensembl biotype	protein_coding
OMIM	613433
Entrez	54801

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 protein_coding

ENST00000380496, ENST00000380502, ENST00000415524, ENST00000888738, ENST00000888739, ENST00000888740, ENST00000888741

RefSeq mRNA: 2 — MANE Select: NM_017645 NM_001270890, NM_017645

CCDS: CCDS6489

Canonical transcript exons

ENST00000380502 — 17 exons

Exon	Start	End
ENSE00001023228	19080479	19080672
ENSE00001023231	19076602	19076704
ENSE00001023233	19060088	19060223
ENSE00001132325	19070219	19070300
ENSE00001132337	19078176	19078302
ENSE00001187310	19057961	19059001
ENSE00001619498	19086734	19086782
ENSE00001626477	19087091	19087156
ENSE00001651449	19094317	19094395
ENSE00001690707	19096674	19096769
ENSE00001701954	19093171	19093303
ENSE00001719386	19082873	19083043
ENSE00001798413	19089412	19089559
ENSE00001826036	19102524	19102904
ENSE00001927739	19053141	19056404
ENSE00003533905	19063008	19063193
ENSE00003634628	19063514	19063580

Expression profiles

Bgee: expression breadth ubiquitous, 242 present calls, max score 89.77.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.0957 / max 86.9215, expressed in 1780 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
100147	11.5851	1780
100146	0.4958	299
100145	0.0083	3
100148	0.0066	4

Top tissues by expression

254 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ganglionic eminence	UBERON:0004023	89.77	gold quality
ventricular zone	UBERON:0003053	89.74	gold quality
epithelial cell of pancreas	CL:0000083	89.16	gold quality
endothelial cell	CL:0000115	88.02	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.38	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.37	gold quality
germinal epithelium of ovary	UBERON:0001304	86.94	gold quality
parietal pleura	UBERON:0002400	85.65	gold quality
visceral pleura	UBERON:0002401	83.06	gold quality
calcaneal tendon	UBERON:0003701	82.81	gold quality
adrenal tissue	UBERON:0018303	82.68	gold quality
right testis	UBERON:0004534	82.59	gold quality
Brodmann (1909) area 23	UBERON:0013554	82.57	gold quality
medial globus pallidus	UBERON:0002477	82.56	gold quality
testis	UBERON:0000473	82.52	gold quality
cortical plate	UBERON:0005343	82.08	gold quality
left testis	UBERON:0004533	81.56	gold quality
tendon	UBERON:0000043	81.39	gold quality
tibia	UBERON:0000979	81.35	gold quality
skin of hip	UBERON:0001554	80.74	gold quality
stromal cell of endometrium	CL:0002255	80.46	gold quality
islet of Langerhans	UBERON:0000006	80.42	gold quality
tibialis anterior	UBERON:0001385	80.32	silver quality
palpebral conjunctiva	UBERON:0001812	80.26	gold quality
smooth muscle tissue	UBERON:0001135	80.18	gold quality
endometrium	UBERON:0001295	79.76	gold quality
primary visual cortex	UBERON:0002436	79.62	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	79.43	gold quality
leukocyte	CL:0000738	79.38	gold quality
monocyte	CL:0000576	79.22	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.00
E-MTAB-4850	no	753.37

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

107 targeting HAUS6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-8075	99.97	67.20	962
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 99.1% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 5)

• Results suggest that an important mitotic function for gamma-tubulin may lie within the spindle, where augmin (Dgt2-6; FAM29A) and gamma-tubulin function cooperatively to amplify the number of microtubules. (PMID:18443220)
• FAM29A promotes microtubule amplification via recruitment of the NEDD1-gamma-tubulin complex to the mitotic spindle. (PMID:19029337)
• Hice1 and hDgt6 are core components of distinct augmin sub-complexes. (PMID:25173975)
• Our work shows that noncentrosomal microtubules nucleation is the predominant source of spindle microtubules also in human somatic cells. Importantly, our analysis of HAUS6-depleted cells shows that the Augmin complex is responsible for this activity. (PMID:31113824)
• Bioinformatics analysis and validation of HAUS6 as a key prognostic gene in squamous cell carcinoma of the tongue. (PMID:38759391)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	haus6	ENSDARG00000101652
mus_musculus	Haus6	ENSMUSG00000038047
rattus_norvegicus	Haus6	ENSRNOG00000046028
drosophila_melanogaster	dgt6	FBGN0039638

Protein

Protein identifiers

HAUS augmin-like complex subunit 6 — Q7Z4H7 (reviewed: Q7Z4H7)

All UniProt accessions (3): Q7Z4H7, Q5SYF9, Q5VY60

UniProt curated annotations — full annotation on UniProt →

Function. Contributes to mitotic spindle assembly, maintenance of centrosome integrity and completion of cytokinesis as part of the HAUS augmin-like complex. Promotes the nucleation of microtubules from the spindle through recruitment of NEDD1 and gamma-tubulin.

Subunit / interactions. Component of the HAUS augmin-like complex. The complex interacts with the gamma-tubulin ring complex and this interaction is required for spindle assembly. Interacts with PLK1, NEDD1 and gamma-tubulin. Interacts with EML3 (phosphorylated at ‘Thr-881’).

Subcellular location. Cytoplasm. Cytoskeleton. Spindle. Microtubule organizing center. Centrosome.

Post-translational modifications. Phosphorylated during mitosis.

Similarity. Belongs to the HAUS6 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q7Z4H7-1	1	yes
Q7Z4H7-2	2
Q7Z4H7-3	3

RefSeq proteins (2): NP_001257819, NP_060115* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026797	HAUS_6	Family
IPR028163	HAUS_6_N	Domain

Pfam: PF14661

UniProt features (35 total): modified residue 15, sequence conflict 8, region of interest 3, splice variant 3, sequence variant 3, chain 1, coiled-coil region 1, compositionally biased region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
7SQK	ELECTRON MICROSCOPY	8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7Z4H7-F1	56.75	0.10

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (15): 550, 552, 584, 715, 728, 742, 805, 823, 908, 914, 943, 406, 507, 524, 530

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-2565942	Regulation of PLK1 Activity at G2/M Transition
R-HSA-380259	Loss of Nlp from mitotic centrosomes
R-HSA-380270	Recruitment of mitotic centrosome proteins and complexes
R-HSA-380284	Loss of proteins required for interphase microtubule organization from the centrosome
R-HSA-380320	Recruitment of NuMA to mitotic centrosomes
R-HSA-5620912	Anchoring of the basal body to the plasma membrane
R-HSA-8854518	AURKA Activation by TPX2

MSigDB gene sets: 174 (showing top): RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, LEE_NEURAL_CREST_STEM_CELL_DN, GOBP_REGULATION_OF_PROTEIN_POLYMERIZATION, GOBP_REGULATION_OF_MICROTUBULE_BASED_PROCESS, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, PAL_PRMT5_TARGETS_UP, GOBP_MICROTUBULE_NUCLEATION, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOLDRATH_ANTIGEN_RESPONSE, WEI_MYCN_TARGETS_WITH_E_BOX, GOBP_REGULATION_OF_MICROTUBULE_POLYMERIZATION, GOCC_CENTROSOME, GOBP_REGULATION_OF_PROTEIN_CONTAINING_COMPLEX_ASSEMBLY, GOBP_ORGANELLE_ASSEMBLY

GO Biological Process (5): microtubule cytoskeleton organization (GO:0000226), centrosome cycle (GO:0007098), regulation of microtubule nucleation (GO:0010968), spindle assembly (GO:0051225), cell division (GO:0051301)

GO Molecular Function (2): microtubule binding (GO:0008017), protein binding (GO:0005515)

GO Cellular Component (8): centrosome (GO:0005813), cytosol (GO:0005829), HAUS complex (GO:0070652), mitotic spindle microtubule (GO:1990498), cytoplasm (GO:0005737), spindle (GO:0005819), cytoskeleton (GO:0005856), microtubule (GO:0005874)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
G2/M Transition	2
Centrosome maturation	2
Loss of proteins required for interphase microtubule organization from the centrosome	1
Mitotic Prometaphase	1
Assembly of the 9+0 primary cilium	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
microtubule cytoskeleton	2
intracellular membraneless organelle	2
cytoskeleton organization	1
microtubule-based process	1
cell cycle process	1
microtubule organizing center organization	1
microtubule nucleation	1
regulation of microtubule polymerization	1
spindle organization	1
chromosome segregation	1
membraneless organelle assembly	1
cellular process	1
tubulin binding	1
binding	1
centriole	1
microtubule organizing center	1
cytoplasm	1
microtubule associated complex	1
spindle microtubule	1
mitotic spindle	1
intracellular anatomical structure	1
polymeric cytoskeletal fiber	1

Protein interactions and networks

STRING

1442 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HAUS6	HAUS8	Q9BT25	977
HAUS6	NEDD1	Q8NHV4	977
HAUS6	HAUS3	Q68CZ6	971
HAUS6	HAUS5	O94927	956
HAUS6	HAUS1	Q96CS2	939
HAUS6	HAUS7	Q99871	934
HAUS6	NUMA1	Q14980	919
HAUS6	HAUS4	Q9H6D7	902
HAUS6	HAUS2	Q9NVX0	877
HAUS6	TUBG1	P23258	871
HAUS6	NDC80	O14777	794
HAUS6	PSMD8	P48556	749
HAUS6	UCHL5	Q9Y5K5	648
HAUS6	CEP192	Q8TEP8	614
HAUS6	PLK1	P53350	610

IntAct

228 interactions, top by confidence:

A	B	Type	Score
MED4	MED19	psi-mi:“MI:2364”(proximity)	0.900
CEP290	CCP110	psi-mi:“MI:2364”(proximity)	0.890
HAUS6	HAUS2	psi-mi:“MI:0915”(physical association)	0.880
HAUS2	HAUS6	psi-mi:“MI:0915”(physical association)	0.880
HAUS6	HAUS8	psi-mi:“MI:0915”(physical association)	0.850
HAUS6	HAUS8	psi-mi:“MI:0407”(direct interaction)	0.850
HAUS8	HAUS6	psi-mi:“MI:0407”(direct interaction)	0.850
HAUS6	HAUS1	psi-mi:“MI:0915”(physical association)	0.810
HAUS1	HAUS6	psi-mi:“MI:0915”(physical association)	0.810
HAUS1	HAUS5	psi-mi:“MI:0915”(physical association)	0.780
HAUS1	HAUS5	psi-mi:“MI:0914”(association)	0.780
HAUS6	HAUS7	psi-mi:“MI:0915”(physical association)	0.770
HAUS2	HAUS5	psi-mi:“MI:0914”(association)	0.730
HAUS6	HAUS5	psi-mi:“MI:0915”(physical association)	0.710
HAUS6	HAUS3	psi-mi:“MI:0915”(physical association)	0.710
HAUS6	HAUS5	psi-mi:“MI:0914”(association)	0.710
HAUS6	HAUS4	psi-mi:“MI:0915”(physical association)	0.710

BioGRID (226): HAUS6 (Affinity Capture-MS), HAUS6 (Affinity Capture-MS), HAUS6 (Affinity Capture-MS), HAUS6 (Reconstituted Complex), HAUS6 (Proximity Label-MS), HAUS6 (Proximity Label-MS), HAUS6 (Proximity Label-MS), HAUS6 (Proximity Label-MS), HAUS6 (Proximity Label-MS), HAUS6 (Proximity Label-MS), HAUS6 (Proximity Label-MS), HAUS6 (Proximity Label-MS), HAUS6 (Proximity Label-MS), HAUS6 (Proximity Label-MS), HAUS6 (Proximity Label-MS)

ESM2 similar proteins: A0A0M3U1B0, A0A1L8EYB2, A0JMF7, A1L2Y1, A2ALV5, A9JRX0, B2GUZ2, D3ZSP7, F1QB81, O35892, O70608, O75113, P23497, P70347, Q0P5X5, Q13129, Q16533, Q2T9I9, Q3U1D0, Q5CZC0, Q5H9M0, Q5REF4, Q5RHB5, Q5SW75, Q5T4T6, Q5T5J6, Q5XG69, Q5ZLE9, Q60664, Q63HN8, Q7M6U3, Q7Z4H7, Q80VH0, Q8BVK9, Q8C263, Q8CCC3, Q8NA03, Q90WN7, Q92844, Q96QP1

Diamond homologs: A0JMF7, Q7Z4H7

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
HAUS6	up-regulates	Microtubule_polimerization
HAUS6	“up-regulates activity”	NEDD1	binding
HAUS6	“form complex”	“HAUS complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 172 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Loss of Nlp from mitotic centrosomes	20	33.0×	1e-23
Loss of proteins required for interphase microtubule organization from the centrosome	20	33.0×	1e-23
AURKA Activation by TPX2	20	31.7×	3e-23
Recruitment of mitotic centrosome proteins and complexes	20	28.3×	3e-22
Anchoring of the basal body to the plasma membrane	24	28.3×	2e-26
Regulation of PLK1 Activity at G2/M Transition	20	26.4×	1e-21
Recruitment of NuMA to mitotic centrosomes	20	24.3×	5e-21

GO biological processes:

GO term	Partners	Fold	FDR
centriole replication	8	40.1×	3e-09
centrosome cycle	11	25.4×	2e-10
spindle assembly	8	24.3×	2e-07
non-motile cilium assembly	7	13.9×	6e-05
cilium assembly	13	6.5×	1e-05
cell division	19	6.0×	8e-08
protein transport	13	3.9×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

179 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	142
Likely benign	10
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

2613 predictions. Top by Δscore:

Variant	Effect	Δscore
9:19058911:T:TA	donor_gain	1.0000
9:19060082:A:C	donor_gain	1.0000
9:19060084:TTACT:T	donor_loss	1.0000
9:19060085:TACT:T	donor_loss	1.0000
9:19060086:A:AC	donor_gain	1.0000
9:19060086:A:T	donor_loss	1.0000
9:19060086:ACT:A	donor_gain	1.0000
9:19060087:C:CG	donor_gain	1.0000
9:19060087:CT:C	donor_gain	1.0000
9:19060087:CTC:C	donor_gain	1.0000
9:19060087:CTCA:C	donor_gain	1.0000
9:19060087:CTCAA:C	donor_gain	1.0000
9:19060090:A:AC	donor_gain	1.0000
9:19060091:A:C	donor_gain	1.0000
9:19060219:GCAAC:G	acceptor_gain	1.0000
9:19060220:CAAC:C	acceptor_gain	1.0000
9:19060220:CAACC:C	acceptor_gain	1.0000
9:19060221:AAC:A	acceptor_gain	1.0000
9:19060222:AC:A	acceptor_gain	1.0000
9:19060223:CC:C	acceptor_gain	1.0000
9:19060223:CCTAA:C	acceptor_loss	1.0000
9:19060224:C:CA	acceptor_loss	1.0000
9:19060224:C:CC	acceptor_gain	1.0000
9:19060230:C:CT	acceptor_gain	1.0000
9:19060231:A:T	acceptor_gain	1.0000
9:19063002:TCTCA:T	donor_loss	1.0000
9:19063003:CTCA:C	donor_loss	1.0000
9:19063004:TCACC:T	donor_loss	1.0000
9:19063005:CACC:C	donor_loss	1.0000
9:19063006:AC:A	donor_loss	1.0000

AlphaMissense

6359 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:19094353:G:C	F89L	0.995
9:19094353:G:T	F89L	0.995
9:19094355:A:G	F89L	0.995
9:19094351:C:G	R90P	0.994
9:19093235:A:C	F124L	0.993
9:19093235:A:T	F124L	0.993
9:19093237:A:G	F124L	0.993
9:19093203:A:T	V135D	0.991
9:19096760:A:C	F46L	0.990
9:19096760:A:T	F46L	0.990
9:19096762:A:G	F46L	0.990
9:19078229:A:G	W380R	0.989
9:19078229:A:T	W380R	0.989
9:19094354:A:G	F89S	0.988
9:19093227:A:G	L127P	0.985
9:19094334:A:G	W96R	0.985
9:19094334:A:T	W96R	0.985
9:19096718:A:C	F60L	0.983
9:19096718:A:T	F60L	0.983
9:19096720:A:G	F60L	0.983
9:19083031:A:G	W238R	0.982
9:19083031:A:T	W238R	0.982
9:19093260:A:G	F116S	0.982
9:19094332:C:A	W96C	0.981
9:19094332:C:G	W96C	0.981
9:19078241:A:G	W376R	0.980
9:19078241:A:T	W376R	0.980
9:19094388:A:G	W78R	0.980
9:19094388:A:T	W78R	0.980
9:19096716:A:G	L61S	0.980

dbSNP variants (sampled 300 via entrez): RS1000010902 (9:19062902 A>C,G), RS1000019067 (9:19086447 T>A), RS1000026334 (9:19094347 T>A,C), RS1000059650 (9:19098462 A>G), RS1000069868 (9:19086257 G>C,T), RS1000128428 (9:19054181 G>C), RS1000134442 (9:19090137 A>G), RS1000246637 (9:19090615 G>A), RS1000251034 (9:19089904 G>A), RS1000283731 (9:19094779 T>A), RS1000400828 (9:19094984 C>G,T), RS1000454240 (9:19085273 A>G), RS1000479529 (9:19067534 A>G), RS1000501251 (9:19080734 T>A,C), RS1000543982 (9:19078632 A>G)

Disease associations

OMIM: gene MIM:613433 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST006085_39	Prostate cancer	7.000000e-14
GCST006089_7	Prostate cancer (early onset)	8.000000e-07
GCST006629_69	Pulse pressure	4.000000e-11
GCST007269_103	Pulse pressure	7.000000e-11
GCST009379_126	Type 2 diabetes	3.000000e-10
GCST011320_19	Type 2 diabetes or prostate cancer (pleiotropy)	1.000000e-14
GCST90002395_51	Mean platelet volume	2.000000e-18
GCST90002402_104	Platelet count	7.000000e-13

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0005763	pulse pressure measurement
EFO:0004309	platelet count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, increases methylation, decreases expression	3
trichostatin A	affects cotreatment, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
Cyclosporine	decreases expression, increases expression	2
Cadmium Chloride	decreases expression, increases abundance	2
FR900359	increases phosphorylation	1
TL8-506	affects cotreatment, increases expression	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
arsenite	affects binding, decreases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	decreases expression	1
coumarin	increases phosphorylation	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	decreases methylation	1
Bortezomib	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Decitabine	decreases expression, affects reaction	1
Arsenic Trioxide	decreases expression	1
Leflunomide	increases expression	1
Acetaminophen	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Azathioprine	decreases expression	1
Benzo(a)pyrene	decreases expression	1
Cadmium	decreases expression, increases abundance	1
Caffeine	affects phosphorylation	1
Calcitriol	decreases expression, affects cotreatment	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.